Trial Profile
A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 27 Mar 2024 Results published in the TellBio Media Release
- 27 Mar 2024 According to a TellBio Media Release, data from this study was published in JCO Precision Oncology.
- 27 Mar 2024 Results presented in a TellBio Media Release.